Polymyositis
MONDO:0019127A rare idiopathic inflammatory myopathy characterized by symmetric proximal muscle weakness and elevated muscle enzymes.
Also known as: PM, polymyositis
102 clinical trials for this condition and its sub-types, 36 tagged with Polymyositis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Polymyositis
-
Dermatomyositis 81 trials · 100 incl. sub-types
11 sub-types
- Juvenile dermatomyositis 41 trials
- Anti-MDA5 dermatomyositis 3 trials
- Clinically amyopathic dermatomyositis 1 trial · 2 incl. sub-types Sub-types →
- Adermatopathic dermatomyositis 0 trials
- Adult dermatomyositis 0 trials
- Anti-Mi2 dermatomyositis 0 trials
- Anti-NXP2 dermatomyositis 0 trials
- Anti-SAE dermatomyositis 0 trials
- Anti-TIF1 dermatomyositis 0 trials
- Classical dermatomyositis 0 trials
- Neonatal dermatomyositis 0 trials
-
Juvenile polymyositis 3 trials
Most studied deeper sub-types
-
Can a One-Time cell therapy reset the immune system in autoimmune disease?
Cure Not yet recruitingThis trial is testing an experimental treatment called CRT-402 for people with severe autoimmune diseases like lupus, scleroderma, and myositis that haven't improved with standard therapies. CRT-402 is a type of CAR-T cell therapy given by infusion that aims to deplete certain im…
Phase 1/2 • Sponsor: Myeloid Therapeutics • Aim: Cure
Last updated Aug 23, 2026 00:00 UTC
-
Can a new pill ease muscle weakness in myositis?
Disease control Not yet recruitingThis phase III trial tests whether the oral drug nerandomilast can improve symptoms of idiopathic inflammatory myopathies, a group of rare autoimmune diseases that cause muscle weakness and inflammation. Adults with active myositis are randomly assigned to take nerandomilast or a…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can engineered immune cells tame stubborn autoimmune diseases?
Disease control Not yet recruitingThis phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…
Phase 1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
HIV drug repurposed to fight muscle inflammation
Disease control Not yet recruitingThis study tests whether Maraviroc, a drug currently used for HIV, can reduce muscle inflammation and improve function in adults with myositis that hasn't responded to standard treatments. Ten participants will take a daily 300mg tablet for 12 weeks and undergo muscle biopsies an…
Phase 4 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Promising drug could save lives in rare, deadly lung disease
Disease control Not yet recruitingThis study tests a drug called teclistamab in 24 adults with a severe, rapidly worsening lung disease linked to anti-MDA5 antibodies. The disease has a very poor outlook, with only about 25% of patients surviving 90 days without a lung transplant. Teclistamab aims to improve surv…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immune retraining: could CAR-Treg cells tame autoimmune disease?
Disease control Not yet recruitingThis early-phase study tests a new treatment called BEN301, which uses specially engineered immune cells (CAR-Tregs) to calm overactive immune responses in people with autoimmune diseases like scleroderma, rheumatoid arthritis, lupus, and inflammatory muscle disease. The trial wi…
Early phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can better sleep ease pain in teens with rheumatic disease?
Symptom relief Not yet recruitingThis study explores whether a self-guided web program called 'Better Nights, Better Days for Youth' can improve sleep and reduce pain in teenagers with rheumatic diseases like arthritis and lupus. Teens aged 12-18 with sleep problems will track their sleep and pain daily, then us…
Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can an online program help young people with lupus and dermatomyositis feel less stressed?
Symptom relief Not yet recruitingThis study tests a new online program called TEAM-LEADS designed to help teens and young adults (ages 13-22) with lupus or dermatomyositis reduce stress and improve heart-healthy behaviors like diet, exercise, and sleep. The program is self-guided and completed online. The study …
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Hypnosis may replace pills for Needle-Phobic kids
Symptom relief Not yet recruitingThis study tests whether hypnotherapy can reduce pain and anxiety in children aged 6 to 18 during needle procedures like injections or blood draws. About 70 kids with conditions like juvenile arthritis or lupus will be randomly assigned to receive either hypnotherapy or standard …
Sponsor: Aarhus University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Blood markers may spot Kids' lung disease earlier
Knowledge-focused Not yet recruitingThis study looks at whether two substances in the blood, IL-6 and MMP-7, can help doctors diagnose and predict the course of a rare lung disease in children. Researchers will measure these markers in 60 children with immune-mediated interstitial lung disease and compare them to h…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New eye on muscle disease: could a quick scan replace weeks of waiting?
Knowledge-focused Not yet recruitingThis study tests a new imaging technique called full-field OCT to see if it can spot muscle inflammation faster than the usual method, which takes weeks. Researchers will compare both methods on muscle samples from 20 healthy adults and people with suspected myositis. The goal is…
Sponsor: Centre Hospitalier de Mâcon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC